BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of ...

BioLife Solutions, Inc. (BLFS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

BioLife Solutions (NASDAQ:BLFS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Monday. Other research analysts ...

StockNews.com upgraded shares of BioLife Solutions (NASDAQ:BLFS – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning. Several other equities ...

07:06 EST BioLife Solutions (BLFS) sees FY25 revenue $95.5M-$99M, consensus $95.46M See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

Detailed price information for Biolife Solutions (BLFS-Q) from The Globe and Mail including charting and trades.

Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call. [Operator Instructions] I ...

BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions (BLFS), Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for ...

Transaction value based on SEC Form 4 weighted average sale price ($25.72); post-transaction value based on Dec. 4 market close of $25.83 (price not specified in filing). BioLife Solutions is a ...